2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
5
Phase 1
5
Phase 3
3
Phase EARLY_PHASE1
1
Phase 2
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
2
Breast
1
Conditions
Prostatic Neoplasms
2
Advanced Breast Cancer
1
Interventions
Cisplatin
726
Carboplatin
609
Paclitaxel
579
Cyclophosphamide
516
Radiotherapy
511
Docetaxel
477
Fluorouracil
454
Gemcitabine
438
Doxorubicin
383
Capecitabine
362
Dexamethasone
328
Oxaliplatin
289
pembrolizumab
283
Leucovorin
283
Bevacizumab
275
Etoposide
272
Vincristine
270
Rituximab
246
Prednisone
223
Pemetrexed
217
Cytarabine
205
Drug Therapy
194
Trastuzumab
176
Irinotecan
174
Methotrexate
171
Lenalidomide
137
Nivolumab
136
Filgrastim
135
Epirubicin
129
Tamoxifen
128
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
AZD5305
×
Clear all
NCT06120491
2026-05-27
EvoPAR-PR01
AstraZeneca
Phase 3
Active not recruiting
1,889 enrolled
NCT06952803
2026-05-19
EvoPAR-PR02
AstraZeneca
Phase 3
Recruiting
700 enrolled
NCT06380751
2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3
Recruiting
500 enrolled